EVH Q2 Deep Dive: Revenue Falls Short, Guidance Cut as Margin Initiatives Continue

Healthcare solutions company Evolent Health (NYSE:EVH) missed Wall Street’s revenue expectations in Q2 CY2025, with sales falling 31.3% year on year to $444.3 million. Next quarter’s revenue guidance of $470 million underwhelmed, coming in 12.9% below analysts’ estimates. Its non-GAAP loss of $0.10 per share was significantly below analysts’ consensus estimates.

Is now the time to buy EVH? Find out in our full research report (it’s free).

StockStory’s Take

Evolent Health’s second quarter was marked by a negative market reaction after the company missed Wall Street’s revenue and earnings expectations. Management attributed the underperformance primarily to delays in partner contract go-lives and unfavorable revenue updates related to prior-year contracts. CEO Seth Blackley acknowledged the challenging macro environment, stating the company faced “the highest per member per month trend that we have seen in oncology in the history of our company,” underscoring industry headwinds and the need for disciplined execution.

Looking ahead, Evolent Health’s updated guidance reflects a cautious approach as management factors in persistent industry volatility and uncertainties in healthcare utilization trends. The company is focused on ramping new partner agreements, expanding its AI-driven automation initiatives, and capitalizing on Medicare Advantage market growth. CFO John Johnson emphasized, “We are maintaining a conservative approach to reserving and forecasting for the guide for Q3 and Q4, but are currently encouraged by our performance so far this year,” signaling a balance between risk management and growth opportunities.

Key Insights from Management’s Remarks

Management highlighted that delays in contract go-lives, evolving customer needs, and elevated medical trends were key factors impacting quarterly performance and the company’s revised outlook.

• Contract go-live delays: Management cited timing issues with a Performance Suite partner, where a local regulatory matter postponed expected revenue, though this has since been resolved and is scheduled to launch in September.
• Oncology cost pressures: The company noted a historic high in per-member oncology costs, but was able to partially offset this with disciplined contract structuring and adherence to evidence-based medicine, which helped keep expenses below forecast.
• AI and automation progress: Evolent continued integrating its recently acquired AI-driven claims review solution, improving review efficiency by 11% last quarter, and is targeting 80% automation of authorization volume within two years.
• Pipeline and new business: Four new revenue agreements were signed in the quarter, including a notable partnership with Aetna for Medicare Advantage in Florida. Management expects these deals to generate over $250 million in new revenue once fully live.
• Risk mitigation in contracts: All new Performance Suite contracts now include enhanced protections such as liability caps and standardized data flows, aiming to reduce exposure to unfavorable trends and ensure more predictable outcomes for both Evolent and its partners.

Drivers of Future Performance

Evolent’s guidance is driven by new business onboarding, increased focus on Medicare Advantage, and ongoing efforts to automate and streamline care management.

• Medicare Advantage expansion: Management highlighted that the majority of booked revenue growth for next year is concentrated in Medicare Advantage, with expectations of macro tailwinds from stabilized membership and a favorable rate environment.
• AI-driven operational efficiency: The company aims to leverage its AI investments to achieve a net $20 million annualized EBITDA improvement by year-end, with the broader goal of automating 80% of clinical authorizations and enhancing both member experience and cost control.
• Contract protections and diversified pipeline: All prospective Performance Suite deals are structured under new risk models, providing enhanced downside protection while the company actively diversifies its client base across national, regional, and Blue plans and specialties, particularly oncology.

Catalysts in Upcoming Quarters

In the coming quarters, our team will focus on (1) the pace at which new partner agreements, especially the Aetna Medicare Advantage contract, are onboarded and ramped; (2) measurable efficiency gains from expanded AI-driven automation initiatives; and (3) trends in medical utilization and contract profitability, particularly in oncology. Policy changes and the evolving regulatory environment for prior authorization will also be closely monitored for their potential impact on both revenue and margins.

Evolent Health currently trades at $9.25, down from $9.69 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

Stocks That Trumped Tariffs

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.